Effects of Immunosuppressive Drugs on Platelet Aggregation and Soluble P-Selectin Levels in Renal Transplant Patients
Open Access
- 1 January 2009
- journal article
- research article
- Published by Taylor & Francis in Renal Failure
- Vol. 31 (2), 111-117
- https://doi.org/10.1080/08860220802599163
Abstract
Background/aim. Post-transplant cardiovascular events are associated with increased morbidity and mortality after renal transplantation. Though renal transplantation eliminates cardiovascular disease risk factors by restoring renal function, it introduces new cardiovascular risks derived partly from immunosuppressive medications. In this study, to assess the effects of various immunosuppressive drugs on platelet function of renal transplant patients, we measured soluble P selectin levels (sP-selectin) and performed platelet aggregation studies in patients who have undergone renal transplantation. Methods. sP-selectin levels and platelet aggregation induced by 5 μM adenosine diphosphate (ADP), 5 μM epinephrine, 1.25 mg/mL ristocetin, and 2 μg/mL collagen were studied by whole blood platelet lumi-aggregometer in 40 renal transplant patients. Patients in group 1 (n = 24) were treated with cyclosporine/mycophenolate mofetil/methylprednisolone, and group 2 (n = 16) were treated with tacrolimus/mycophenolate mofetil/methylprednisolone. Effects were compared with those in control groups of hypertensive subjects and healthy subjects. Results. Platelet aggregation values induced by ADP, epinephrine, ristocetin, and collagen were lower in cyclosporine-treated patients than tacrolimus-treated patients, hypertensive subjects, and healthy subjects, though the difference was not statistically significant (p > 0.05). sP-selectin levels were appreciably higher in cyclosporine-treated patients, and statistically significant differences were observed compared with those of tacrolimus-treated patients (p < 0.05), hypertensive subjects (p < 0.01), and healthy subjects (p < 0.05). Conclusion. We conclude that cyclosporine-treated renal transplant patients show enhanced platelet activation in which anti-platelet therapy should be considered, in addition to management of other conventional cardiovascular risk factors, to decrease the cardiovascular morbidity and mortality in this high risk population.Keywords
This publication has 18 references indexed in Scilit:
- Cardiovascular Disease PosttransplantSeminars in Nephrology, 2007
- Association of chronic kidney graft failure with recipient blood pressureKidney International, 1998
- Increased soluble P-selectin following myocardial infarctionBlood Coagulation & Fibrinolysis, 1997
- Hypothesis: is soluble P-selectin a new marker of platelet activation?Atherosclerosis, 1997
- Evolution of cardiovascular risk after liver transplantation: A comparison of cyclosporine A and tacrolimus (FK506)Liver Transplantation and Surgery, 1997
- THE COAGULO-LYTIC SYSTEM AND ENDOTHELIAL FUNCTION IN CYCLOSPORINE-TREATED KIDNEY ALLOGRAFT RECIPIENTSTransplantation, 1996
- Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipientsNephrology Dialysis Transplantation, 1996
- Cyclosporine A enhances platelet aggregationKidney International, 1987
- The Pathogenesis of Atherosclerosis — An UpdateNew England Journal of Medicine, 1986
- THROMBOEMBOLIC COMPLICATIONS AND HAEMOSTATIC CHANGES IN CYCLOSPORIN-TREATED CADAVERIC KIDNEY ALLOGRAFT RECIPIENTSThe Lancet, 1985